Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Recommendation of “Buy” from Analysts

Dyne Therapeutics, Inc. (NASDAQ:DYN) has been given a consensus recommendation of “Buy” by the thirteen research firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold recommendation, ten have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $49.91.

A number of equities research analysts have issued reports on DYN shares. Guggenheim reaffirmed a “buy” rating on shares of Dyne Therapeutics in a report on Friday, January 24th. Chardan Capital reaffirmed a “buy” rating and set a $50.00 price objective on shares of Dyne Therapeutics in a report on Friday, January 10th. JPMorgan Chase & Co. lowered shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $43.00 to $35.00 in a report on Thursday, October 24th. Raymond James raised shares of Dyne Therapeutics to a “strong-buy” rating in a report on Thursday, December 12th. Finally, HC Wainwright reissued a “buy” rating and issued a $55.00 target price on shares of Dyne Therapeutics in a report on Friday, January 10th.

Dyne Therapeutics Trading Down 1.5 %

NASDAQ DYN opened at $13.46 on Friday. Dyne Therapeutics has a 12 month low of $13.23 and a 12 month high of $47.45. The stock has a market cap of $1.37 billion, a price-to-earnings ratio of -3.78 and a beta of 1.16. The company’s 50 day moving average is $23.39 and its two-hundred day moving average is $32.15.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). Sell-side analysts forecast that Dyne Therapeutics will post -3.44 EPS for the current year.

Insiders Place Their Bets

In other news, insider Oxana Beskrovnaya sold 2,334 shares of Dyne Therapeutics stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total transaction of $65,632.08. Following the completion of the sale, the insider now directly owns 201,685 shares in the company, valued at approximately $5,671,382.20. This trade represents a 1.14 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Richard William Scalzo sold 1,455 shares of Dyne Therapeutics stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total value of $40,914.60. Following the sale, the senior vice president now owns 127,078 shares of the company’s stock, valued at approximately $3,573,433.36. This trade represents a 1.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 21,071 shares of company stock valued at $606,476 over the last three months. 20.77% of the stock is owned by company insiders.

Institutional Trading of Dyne Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Quantbot Technologies LP bought a new stake in shares of Dyne Therapeutics in the third quarter valued at about $34,000. Point72 DIFC Ltd bought a new stake in shares of Dyne Therapeutics in the third quarter valued at about $36,000. US Bancorp DE raised its holdings in shares of Dyne Therapeutics by 776.9% in the third quarter. US Bancorp DE now owns 1,368 shares of the company’s stock valued at $49,000 after acquiring an additional 1,212 shares in the last quarter. Values First Advisors Inc. bought a new stake in shares of Dyne Therapeutics in the third quarter valued at about $62,000. Finally, KBC Group NV raised its holdings in shares of Dyne Therapeutics by 45.3% in the fourth quarter. KBC Group NV now owns 3,135 shares of the company’s stock valued at $74,000 after acquiring an additional 978 shares in the last quarter. 96.68% of the stock is currently owned by institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.